Medifast Inc (MED) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...

GuruFocus.com11-05

Revenue: $140.2 million, a decrease of 40.6% year-over-year. Gross Profit: $105.7 million, a decrease of 40.4% year-over-year. Gross Profit Margin: Improved by 20 basis points to 75.4%. SG&A Expense: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481681340?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 23:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481681340","market":"us","top_or_hot":-1,"title":"Medifast Inc (MED) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $140.2 million, a decrease of 40.6% year-over-year.\nGross Profit: $105.7 million, a decrease of 40.4% year-over-year.\nGross Profit Margin: Improved by 20 basis points to 75.4%.\nSG&A Expense: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/medifast-inc-med-q3-2024-150034840.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medifast Inc (MED) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedifast Inc (MED) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/medifast-inc-med-q3-2024-150034840.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $140.2 million, a decrease of 40.6% year-over-year.\nGross Profit: $105.7 million, a decrease of 40.4% year-over-year.\nGross Profit Margin: Improved by 20 basis points to 75.4%.\nSG&A Expense: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/medifast-inc-med-q3-2024-150034840.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MED","symbol_name":"快验保","start_time":0,"source_url":"https://finance.yahoo.com/news/medifast-inc-med-q3-2024-150034840.html","article_id":"2481681340","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481681340","pubTimestamp":1730818834,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $140.2 million, a decrease of 40.6% year-over-year.Gross Profit: $105.7 million, a decrease of 40.4% year-over-year.Gross Profit Margin: Improved by 20 basis points to 75.4%.Net Income: $1.1 million or $0.10 per diluted share.Active Earning Optavia Coaches: Approximately 30,000, a decrease of 36.3% from the prior year.Average Revenue per Active Earning Coach: $4,672, a decline of 6.7% year-over-year.Cash and Investments: $170 million with no interest-bearing debt.Fourth Quarter Revenue Guidance: Expected to range from $100 to $120 million.Fourth Quarter Loss per Share Guidance: Expected to range from $0.10 to $0.65.GuruFocus has detected 4 Warning Signs with MED.Medifast Inc  is actively adapting to the changing weight loss market by developing new programs tailored for individuals using GLP-1 medications.A: James Maloney, CFO: We spent $7 million in Q3 and plan to spend another $7 million in Q4, totaling $17 million year-to-date. We've optimized our marketing efforts, focusin","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MED":"快验保"},"translate_title":"快验保公司(MED)2024年第三季度收益看涨期权亮点：通过战略应对挑战……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MED":1},"content_text":"Revenue: $140.2 million, a decrease of 40.6% year-over-year.\nGross Profit: $105.7 million, a decrease of 40.4% year-over-year.\nGross Profit Margin: Improved by 20 basis points to 75.4%.\nSG&A Expense: $103.6 million, down 31.8% year-over-year.\nNet Income: $1.1 million or $0.10 per diluted share.\nAdjusted Net Income: $3.9 million or $0.35 per diluted share.\nActive Earning Optavia Coaches: Approximately 30,000, a decrease of 36.3% from the prior year.\nAverage Revenue per Active Earning Coach: $4,672, a decline of 6.7% year-over-year.\nCash and Investments: $170 million with no interest-bearing debt.\nFourth Quarter Revenue Guidance: Expected to range from $100 to $120 million.\nFourth Quarter Loss per Share Guidance: Expected to range from $0.10 to $0.65.\n\n\nWarning! GuruFocus has detected 4 Warning Signs with MED.\n\nRelease Date: November 04, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nMedifast Inc (NYSE:MED) is actively adapting to the changing weight loss market by developing new programs tailored for individuals using GLP-1 medications.\nThe company has expanded training for Optavia coaches, with over 95% of coach leaders completing specialized training to support clients on GLP-1 medications.\nMedifast Inc (NYSE:MED) plans to launch new products under the Optavia Ascend brand, specifically designed for those on GLP-1 medications, in early 2025.\nThe company maintains a strong balance sheet with $170 million in cash and no interest-bearing debt, providing financial flexibility for future investments.\nMedifast Inc (NYSE:MED) is optimizing its marketing strategy, focusing on channels that yield the highest return on investment, and plans to continue this approach into 2025.\n\n Negative Points \n\nRevenue for the third quarter of 2024 decreased by 40.6% year-over-year, primarily due to a decline in the number of active earning Optavia coaches and lower productivity per coach.\nThe number of active earning Optavia coaches decreased by 36.3% from the third quarter of 2023, impacting customer acquisition.\nMedifast Inc (NYSE:MED) faces significant competition from GLP-1 medications, affecting customer acquisition and spending patterns.\nThe company expects a loss per share for the fourth quarter of 2024, ranging from 10 to 65, indicating continued financial pressure.\nSG&A expenses as a percentage of revenue increased by 950 basis points to 73.9%, reflecting a loss of leverage due to lower sales volumes.\n\n Q & A Highlights \nQ: Can you provide more details on the marketing spend, particularly the areas where you've scaled back and the response from the areas you are still investing in? A: James Maloney, CFO: We spent $7 million in Q3 and plan to spend another $7 million in Q4, totaling $17 million year-to-date. We've optimized our marketing efforts, focusing on channels that yield the highest return on investment. Social media has been effective, and we've seen success in capturing emails from website interactions. However, 90% of our client acquisition still comes through our coach channel. We plan to continue this spend into 2025, especially during resolution season.\nQ: Are there any particular advertising channels that have shown more or less success? A: Daniel Chard, CEO: Social media channels have been highly effective. We've also seen success in capturing emails from website interactions. Despite the new company-led acquisition strategy, 90% of our client acquisition still comes through our coach channel. We've trained 95% of our coach leaders to support GLP-1 medications, and 40% of our coaches now support at least one client on these drugs.\nQ: Why does the guidance for Q4 imply a deceleration in revenue, given the sequential improvement seen throughout the year? A: James Maloney, CFO: We continue to face pressure on client acquisition, impacting the number of coaches. Q4 is typically more challenging due to seasonality, as people are less focused on health and wellness. We've scaled back some company-led acquisition efforts in Q4, aligning our guidance with these seasonal trends.\nQ: Of the 12% of clients on GLP-1 drugs, what portion received their prescriptions through LifeMD? A: Daniel Chard, CEO: We haven't disclosed specific numbers, but it's a mix. Some clients transition off GLP-1 drugs and find us through various channels. We have successful coach groups working closely with LifeMD physicians, and we expect this integration to improve over time.\nQ: What are the expected costs for the clinical studies, and when will this spending occur? A: James Maloney, CFO: Most of the costs for the clinical studies will occur in 2025 and beyond, with initial estimates being less than $2 million. Very little will be spent in Q4. The studies aim to assess the health outcomes of integrating Optavia nutrition and lifestyle programs with medications.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481681340"}